Providers

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

Real-world data suggest nirogacestat boosts response in desmoid tumor vs standard-of-care treatment, but small cohorts leave key outcomes unanswered.

Medicare’s GLP-1 Bridge offers temporary coverage for obesity medication at $50/month, but patients face a 2027 cliff as BALANCE stalls.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Health plan infrastructure and patient reporting are underutilized, powerful tools for identifying food insecurity, Jonathan Wrathall, PhD, argues.

An Institute for Value-Based Medicine® event in Princeton highlights how the state's leading cancer care providers meet the needs of a diverse population.

Ontada research presented at ISPOR 2026 shows the NCCN Distress Thermometer can predict overall survival in metastatic cancers, but the relationship varies by cancer type.

Ontada finds that EHR-based education boosts NCCN guideline-concordant care for patients with HER2-low metastatic cancer, raising targeted treatment use among providers who took part in the education activities.

US health care faces massive shifts: rising ACA deductibles, federal health leadership shakeups, and major care gaps in women's health and dermatology.

A new training framework operationalizes brachytherapy competencies for soft tissue sarcoma, covering implant geometry, CT planning, dose optimization, toxicity management, and radiation safety.

The FDA approves Datroway for first-line metastatic triple-negative breast cancer in immunotherapy-ineligible patients.

This review will appear in the June issue of Evidence-Based Oncology.

From hypofractionation to proton beam therapy to pembrolizumab combinations, a new review details how 2025 reshaped the radiotherapy landscape for soft tissue sarcomas.

Texas Oncology boosts precision medicine with near-universal biomarker testing, quality measurement, and genomic insights—advancing health equity through streamlined workflows and coverage. This commentary will appear in the June issue of Evidence-Based Oncology.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk after, reshaping care.

Women’s Health Month highlights major 2026 shifts in menopause care, brain health, abortion access, doula coverage, and wearable tech.

Health updates cover abortion pill access, lung care research, pregnancy-linked heart risks, US longevity gaps, and flawed drug adherence metrics.

Prior authorization and payer hurdles delay prescription drugs; the Alliance for Patient Access urges health policy shaped by patient experience.

New pediatric guidelines standardize radiation for metastatic rhabdomyosarcoma, detailing site-specific dosing to improve STS outcomes.

Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival.

Community pharmacists must build scalable workflows as bispecific antibodies move into earlier lines and outpatient settings, notes Brooke Peters, PharmD, BCOP, of AON.